

# WHO Expert Committee on Biological Standardization

---

Seventieth report



World Health  
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int); order on line: [www.who.int/bookorders](http://www.who.int/bookorders)).

W H O T e c h n i c a l R e p o r t S e r i e s  
1 0 2 4

# WHO Expert Committee on Biological Standardization

---

Seventieth report

*This report contains the views of an international group of experts and  
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health  
Organization**

WHO Expert Committee on Biological Standardization: seventieth report

(WHO Technical Report Series, no. 1024)

ISBN 978-92-4-000373-6 (electronic version)

ISSN 978-92-4-000374-3 (print version)

ISSN 0512-3054

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** WHO Expert Committee on Biological Standardization: seventieth report. Geneva: World Health Organization; 2020 (WHO Technical Report Series; no. 1024). Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Printed in Malta

# Contents

<b>Abbreviations</b>	xiii
<b>1. Introduction</b>	1
<b>2. General</b>	3
2.1 Current directions	3
2.1.1 Strategic directions in the regulation of medicines and other health technologies: WHO priorities	3
2.1.2 Vaccines and biotherapeutics: recent and planned activities in biological standardization	4
2.1.3 Blood products and in vitro diagnostics: recent and planned activities in biological standardization	6
2.2 Reports	7
2.2.1 Report from the WHO Blood Regulators Network	7
2.3 Feedback from custodian laboratories	9
2.3.1 Developments and scientific issues identified by custodians of WHO biological reference preparations	9
2.4 Cross-cutting activities of other WHO committees and groups	13
2.4.1 Update from the WHO Expert Committee on Specifications for Pharmaceutical Preparations	13
2.4.3 Update on the WHO R&D Blueprint for action to prevent epidemics	15
2.4.4 Update on the activities of the Coalition for Epidemic Preparedness Innovations	15
2.4.5 Update on the WHO pilot procedure for the prequalification of biotherapeutic products and SBPs	16
2.4.6 Update on the WHO Model List of Essential Medicines	18
2.4.7 Update on WHO regulatory systems strengthening activities	19
2.4.8 Update from the WHO Product Development for Vaccines Advisory Committee	20
2.4.9 Report of the October meeting of the Strategic Advisory Group of Experts on Immunization	22
2.4.10 Report of progress made in integrating blood products into the WHO Global Benchmarking Tool	23
2.4.11 Update on the WHO snakebite envenoming strategy	24
2.4.12 Development of reference materials for <i>Plasmodium vivax</i> antigen	25
<b>3. International Recommendations, Guidelines and other matters related to the manufacture, quality control and evaluation of biological substances</b>	27
3.1 General	27
3.1.1 Assessment of commutability in international collaborative studies	27
3.2 Biotherapeutics other than blood products	28
3.2.1 Revision of the WHO Guidelines on evaluation of similar biotherapeutic products (SBPs)	28
3.2.2 Update on the standardization of similar biotherapeutic products	29

3.3	Blood products and related substances	30
3.3.1	WHO Action framework to advance universal access to safe, effective and quality-assured blood products 2020–2023	30
3.4	Cellular and gene therapies	31
3.4.1	Update on the standardization of cellular and gene therapy products	31
3.5	Vaccines and related substances	32
3.5.1	Guidelines on the quality, safety and efficacy of respiratory syncytial virus vaccines	32
3.5.2	Amendment to the WHO Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated)	33
3.5.3	Revision of the WHO Guidelines for the safe production and quality control of poliomyelitis vaccines	35
3.5.4	International collaborative study to investigate the utility of NGS as a molecular test of virus stocks used in the manufacture of oral poliomyelitis vaccines	37
<b>4.</b>	<b>International reference materials – antibiotics</b>	<b>39</b>
4.1	WHO International Standards and Reference Reagents – antibiotics	39
4.1.1	Third WHO International Standard for amphotericin B	39
<b>5.</b>	<b>International reference materials – biotherapeutics other than blood products</b>	<b>41</b>
5.1	WHO International Standards and Reference Reagents – biotherapeutics other than blood products	41
5.1.1	First WHO International Standard for darbepoetin	41
5.1.2	First WHO International Standard for adalimumab	42
5.2	Proposed new projects and updates – biotherapeutics other than blood products	43
5.2.1	Proposed Sixth WHO International Standard for chorionic gonadotrophin (human)	43
5.2.2	Proposed Third WHO International Standard for follicle-stimulating hormone (human, recombinant)	44
5.2.3	Proposed First WHO International Standard for ustekinumab	44
5.2.4	Proposed Third WHO International Standard for interferon alpha-2b	45
<b>6.</b>	<b>International reference materials – blood products and related substances</b>	<b>47</b>
6.1	WHO International Standards and Reference Reagents – blood products and related substances	47
6.1.1	Third WHO International Standard for prekallikrein activator	47
6.1.2	Fourth WHO International Standard for streptokinase	48
6.1.3	Second WHO International Standard for anti-tetanus immunoglobulin (human)	49
6.1.4	First WHO International Standard for blood coagulation factor XIII-B subunit antigen (total, plasma) via assignment of additional analyte to the current First WHO International Standard for blood coagulation factor XIII (plasma)	50
6.1.5	Establishment of RBC13–30 blood group genotyping alleles (lyophilized) as a companion set to the WHO international reference reagent collection for blood group genotyping	51

6.1.6	First WHO Repository of red blood cell transfusion relevant bacterial reference strains	52
6.2	Proposed new projects and updates – blood products and related substances	54
6.2.1	Proposed Second WHO International Standard for plasminogen-activator inhibitor 1 (plasma, human)	54
6.2.2	Proposed Third WHO International Standard for thrombin	55
6.2.3	Proposed First WHO International Reference Reagent for platelet flow cytometry	56
6.2.4	Proposed First WHO International Standard for plasma prekallikrein and high molecular weight kininogen	56
<b>7.</b>	<b>International reference materials – cellular and gene therapies</b>	<b>58</b>
7.1	WHO International Standards and Reference Reagents – cellular and gene therapies	58
7.1.1	First WHO International Reference Panel for lentiviral vector copy number and First WHO International Reference Reagent for lentiviral vector integration site analysis	58
7.2	Proposed new projects and updates – cellular and gene therapies	59
7.2.1	Proposed First WHO International Standard for replication-competent lentivirus	59
7.2.2	Proposed First WHO International Reference Reagent for pluripotent stem cell identity for flow cytometry	59
7.2.3	Update on the proposed First WHO International Reference Reagent for mesenchymal stromal cell identity for flow cytometry	60
<b>8.</b>	<b>International reference materials – in vitro diagnostics</b>	<b>62</b>
8.1	WHO International Standards and Reference Reagents – in vitro diagnostics	62
8.1.1	Sixth WHO International Standard for hepatitis C virus RNA for NAT-based assays	62
8.1.2	First WHO international standards for human papillomavirus DNA for low-risk types 6 and 11, and high-risk types 31, 33, 45, 52 and 58 for NAT-based assays	63
8.1.3	First WHO International Reference Reagent for anti-Müllerian hormone (human, recombinant)	65
8.1.4	Second WHO International Standard for insulin (human)	66
8.1.5	First WHO international standards for HCT 15 cancer genome, MOLT-4 cancer genome and ATDB102 reference genome	67
8.2	Proposed new projects and updates – in vitro diagnostics	68
8.2.1	Proposed First WHO international standards for genomic epidermal growth factor receptor variants	68
8.2.2	Proposed Second WHO International Standard for beta-2 microglobulin (lyophilized)	69
8.2.3	Proposed First WHO International Standard for anti-Q fever serum (human)	70
8.2.4	Proposed First WHO International Standard for Rift Valley fever virus RNA for NAT-based assays	71
8.2.5	Proposed First WHO international reference reagents for microbiome analysis by NGS	71
8.2.6	Proposed First WHO International Standard for Legionella urinary antigen	73

8.2.7	Proposed First WHO International Standard for <i>Aspergillus fumigatus</i> DNA for NAT-based assays	74
8.2.8	Proposed First WHO International Standard for cell-associated HIV nucleic acid and First WHO International Reference Panel for cell-associated HIV nucleic acid	74
8.2.9	Update on the stability of the First WHO International Reference Panel for Ebola virus VP40 antigen	75
<b>9.</b>	<b>International reference materials – vaccines and related substances</b>	<b>77</b>
9.1	WHO International Standards and Reference Reagents – vaccines and related substances	77
9.1.1	First WHO International Standard for EV71 inactivated vaccine, First WHO International Reference Reagent for EV71 genotype C4 inactivated vaccine and First WHO International Reference Reagent for EV71 genotype B4 inactivated vaccine	77
9.1.2	Third WHO International Standard for tetanus toxoid for use in flocculation test	78
9.1.3	Extension of use of the First WHO International Standard for antiserum to respiratory syncytial virus	79
9.1.4	First WHO international standards for meningococcal serogroups W and Y polysaccharide	80
9.2	Proposed new projects and updates – vaccines and related substances	81
9.2.1	Proposed First WHO International Reference Reagent for tetanus antitoxin for the flocculation test	81
9.2.2	Proposed First WHO International Standard for anti-Rift Valley fever virus immunoglobulin	82
9.2.3	Proposed First WHO International Reference Reagent for recombinant pertussis toxoid	83
9.2.4	Proposed Second WHO international reference reagents for MAPREC analysis and NGS of poliovirus types 1, 2 and 3 (Sabin)	84
9.2.5	Update on work towards the First WHO International Standard for antibody to the influenza virus haemagglutinin stem domain	85
<b>Annex 1</b>		
	WHO Recommendations, Guidelines and other documents related to the manufacture, quality control and evaluation of biological substances used in medicine	87

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>